TES Antibody, Biotin conjugated

1. validated two new TES cocomplex partners: TGFB1I1 and a short form of the glucocorticoid receptor. TES and TGFB1I1 are shown to oppositely affect cell spreading providing biological validity for their copresence in complexes since they act in similar processes PMID: 28378594
2. these data indicate that TES functions as a necessary suppressor of colorectal cancer progression by activating p38-MAPK signaling pathways. PMID: 27323777
3. testin region (amino acids 52-233) harbouring the PET domain interacts with the C-terminal LIM1-2 domains PMID: 28542564
4. Testin plays an important role in the development and progression of non-small cell lung cancer. Testin is a tumor suppressor. PMID: 28000866
5. VASP, zyxin and TES are tension-dependent members of focal adherens junctions independent of the alpha-catenin-vinculin module. PMID: 26611125
6. we confirm that the TES promoter is unmethylated in normal adult and fetal tissues. Re-expression of TESTIN protein in acute lymphoblastic leukemia cells using expression plasmid transfection results in rapid cell death or cell cycle arrest. PMID: 26985820
7. Loss of TES gene expression is associated with nasopharyngeal carcinoma. PMID: 25824796
8. findings suggest that the TES gene is a novel tumor suppressor gene PMID: 25498217
9. TESTIN was hypermethylated in 43.7% endometrial cancer tissues (p < 0.001). Moreover, TESTIN hypermethylation was significantly correlated with advanced tumor stage, deep myometrial invasion and lymphatic node metastasis. PMID: 25720371
10. Downregulation of TES was associated with breast cancer. PMID: 25119600
11. TESTIN was commonly downregulated in human endometrial carcinoma and was associated with poor prognostic markers. PMID: 24929083
12. A further significant correlation was observed between TES downregulation and the luminal B subtype independent of survivin expression. PMID: 23715752
13. TES, as a valuable marker of breast cancer prognosis, plays an important role in the development and progression of breast cancer. TES may be an effective novel target in breast cancer prevention and treatment. PMID: 22957844
14. Low TES gene expression is associated with coronary artery disease. PMID: 22156939
15. Alterations of TES mRNA level may predict the location of metastasis. CAV1 possibly affect the cancer cell invasion PMID: 22201996
16. These results suggest an interplay between the CaR and testin in the regulation of CaR-mediated Rho signalling with possible effects on the cytoskeleton. PMID: 21843504
17. data implicate TES methylation in ALL and provide additional evidence for the involvement of LIM domain proteins in leukaemogenesis PMID: 20573277
18. results support the role of TES as a TSG in gastric carcinogenesis and that TES is inactivated primarily by LOH and CpG island methylation PMID: 20626849
19. The expression level of TES is significantly down-regulated in primary gastric cancer. PMID: 18799041
20. TES gene functions as a tumor suppressor gene and is frequently silenced by hypermethylation and loss of heterozygosity in ovarian cancers. PMID: 20180808
21. TES is best candidate tumor suppressor gene at 7q31 in prostate tumors PMID: 15252854
22. Loss of TES from focal adhesions results in loss of actin stress fibres. PMID: 15662727
23. Oservations identify Tes as an atypical binding partner of EVH1 domain of Mena and a regulator specific to a single Ena/VASP family member. PMID: 18158903
24. Results suggest that testin has different conformational states in different cellular compartments, and a "closed" conformational state of TES may be involved in nucleolar localization. PMID: 18696217
25. Inactivation of TESTIN is involved in head and neck carcinogenesis through its downregulation. PMID: 19289703

Show More

Hide All

HGNC: 14620

OMIM: 606085

KEGG: hsa:26136

STRING: 9606.ENSP00000350937

UniGene: Hs.592286